The Bid Defense Is an Audition. Make Sure the Right People Are Auditioning.

A CRO bid defense should test the people who will run your study, not only the people who sell it. The meeting is most valuable when the proposed project lead and functional leads are in the room, answering study-specific questions in their own words. In the ABRA PROOF™ Method, this is the second half of Orchestrate the Bid: every promise is tested with the team that would actually run your study, so every commitment becomes verifiable.

Most bid defenses follow a familiar script. A senior business development lead opens, an executive speaks to commitment, a therapeutic expert presents a compelling case study and the proposed project manager appears briefly near the end. The sponsor leaves impressed. What the sponsor rarely leaves with is evidence of how this specific team will handle this specific study.

Who should attend a CRO bid defense?

Ask for the people named in the proposal to lead your study: the project lead, the clinical operations lead and the leads for data management, medical monitoring or any function critical to your program. Senior executives and business development leaders are welcome, but they should not do most of the talking.

Make the request in writing, ahead of time, and ask the CRO to confirm who will attend and in what role. If a proposed lead cannot attend, ask why, and ask whether that person is truly available for your study.

What questions should you ask at a CRO bid defense?

The best questions are specific to your study and cannot be answered with a prepared slide.

  • Walk us through study startup. What will you need from us, and when?

  • Which assumption in your proposal worries you most?

  • Tell us about a study like ours that went off track. What did you do?

  • How will you escalate a problem to us, and to your own leadership?

  • How many other studies will you be leading at the same time?

Direct each question to the person who will own the answer. If the project lead defers every question to a senior colleague, notice it.

How do you tell rehearsed answers from real capability?

Rehearsed answers are fluent and general. Real capability shows up in specifics: the kinds of sites they would approach, the enrollment risk they see in your eligibility criteria, the vendor handoff they expect to be difficult. A team that has genuinely studied your protocol will raise concerns you did not ask about.

A useful technique is the follow-up question. Ask "why?" or "what would you do if that didn't work?" once or twice. Prepared material runs out quickly. Experience does not.

Also watch how the team interacts. Do functional leads speak with each other naturally, or does it feel like the first time they have worked together? Do they disagree respectfully? Strong teams show their working relationships in the room.

What should happen after the bid defense?

Score the bid defense against the criteria you set before the process began, not against your overall impression. Record the specific commitments made in the room, particularly about named personnel, timelines and escalation. Those commitments belong in the contract, not just in your memory.

Follow up on anything that was deferred. A promise to "come back to you on that" is a test of responsiveness, and the speed and quality of the answer tells you something about how communication will work after award.

What sponsors gain

When the bid defense is orchestrated well, you leave with evidence rather than impressions. You know who would lead your study, how they think about its risks and whether they have the depth to handle the moments when the plan changes. Team continuity is one of the four factors I see derail selections most often, and the bid defense is your best chance to test it before award. That evidence is what separates a confident award from a hopeful one.

For a bid defense scenario worth running, read Inspection Readiness in a Global Industry.

Previous
Previous

Interim Clinical Operations Leadership: Keeping Programs Moving During Transition

Next
Next

Budgets, Change Orders and AI: Can Machine Learning Fix Clinical Trial Cost Overruns?